Table 1.

Differences on sAML classification within WHO22 and ICC22.

Classification criterion	WHO22	ICC22	Remarks
Genetic aberrations	Used for classification; however, secondary myeloid neoplasms have a separate category basing on remote history.	Genetic aberrations are prioritized in defining AML. “Anamnestic qualifiers” may be appointed to any AML diagnosis	ICC22 gives overriding importance to genetic abnormalities.
Blast threshold for AML diagnosis	≥20% blasts (except for molecular-defining cytogenetics abnormalities)	≥10% blasts for certain genetic abnormalities	The blast threshold is inconsistent between ICC22 and WHO22 classifications.
Therapy-related AML	Considered a separate entity basing on remote history	Used as a diagnostic qualifier.	ICC22 shifts focus from clinical history to genetic profile.
Germline-predisposition AML	Considered a separate entity basing on remote history/genetics	Used as a diagnostic qualifier.	There are minor differences in genes acknowledged to give germline predisposition; genes causing some complex syndromes are not accounted in WHO22 classification.
Myelodysplasia-related AML	Used for classification within AML; AML with myelodysplasia-related abnormalities is classified as an AML subcategory (MR-AML)	Used as a diagnostic qualifier. Biological entities of myelodysplasia-related cytogenetics and myelodysplasia-related mutations are accounted as MDS/AML and AML subcategories.	Reflects ICC22’s emphasis on genetic features over clinical history.
AML evolution of other chronic myeloid disorders	It is maintained in the chronic myeloproliferative neoplasms category unless evolutions come from MDS/MPN; in this case, it is classified as MR-AML.	Used as a diagnostic qualifier. Biological entities may be assigned irrespective to remote history if patient has criteria.	WHO22 classification tends to maintain evolution of non-MDS chronic diseases within the chronic disease category.